Abstract

Aim: We aimed to evaluate the dosimetric influence of Acuros XB (AXB) dose-to-medium ($D_m$) and dose-to-water ($D_w$) reporting mode on carcinoma cervix using intensity-modulated radiation therapy (IMRT) and RapidArc (RA) technique. Materials and Methods: A cohort of thirty patients cared for carcinoma cervix was retrospectively selected for the study. Plans were computed using analytical anisotropic algorithm (AAA), AXB-$D_m$ and AXB-$D_w$ algorithms for dosimetric comparison. A paired $t$-test and Pitman–Morgan dispersion test were executed to appraise the difference in mean values and the inter-patient variability of the differences. Results: The dose–volume parameters were higher for AXB-$D_w$ in contrast to AAA for IMRT and RA plans, excluding $D_{98\%}$, minimum dose to planning target volume (PTV) and rectum mean dose (RA). There was no systematic trend observed in dose–volume parameters for PTV and organs at risk (OARs) between AXB-$D_m$ and AXB-$D_w$ for IMRT and RA plans. The dose–volume parameters for target were higher for AXB-$D_w$ in comparison to AAA in IMRT and RA plans, except $D_{98\%}$ and minimum dose to PTV. Analysis envisaged less inter-patient variability while switching from AAA to AXB-$D_m$ in comparison to those switching from AAA to AXB-$D_w$. Conclusions: The present study reveals the important difference between AAA, AXB-$D_m$, and AXB-$D_w$ for PTV and their relative constraints to OARs for IMRT and RA techniques. This may help in the decision-making in clinic while switching from AAA to AXB ($D_m$ or $D_w$) algorithm for cervix carcinoma using IMRT and RA techniques.

Keywords: Algorithm, cervix carcinoma, intensity-modulated radiation therapy, planning, RapidArc

Introduction

In the wake of recent advancements in radiation therapy (RT), intensity-modulated radiation therapy (IMRT) and RapidArc (RA) utilize numerous small beamlets to modulate the radiation beam to be delivered to cancer patients. IMRT and RA techniques are better at promoting organs at risk (OARs) sparing while delivering the intended radiation doses to the tumor targets. To achieve the optimal therapeutic benefit of radiation, IMRT and RA techniques require a precise dose computation engine which can perform a nuanced calculation of the modulations that the radiation beam undergoes when it passes through the heterogeneous medium encountered inside the human body.

Radiation transport and their dose deposition patterns in the medium have direct influence on the dose computation.

Address for correspondence: Dr. Lalit Kumar, Department of Radiation Oncology, Division of Medical Physics, Rajiv Gandhi Cancer Institute and Research Centre, Sector-5, Rohini, New Delhi - 110 085, India.

How to cite this article: Kumar L, Bhushan M, Kishore V, Chowdhary R, Barik S, Sharma A, et al. Dosimetric influence of acuros XB dose-to-medium and dose-to-water reporting modes on carcinoma cervix using intensity-modulated radiation therapy and volumetric rapidArc technique. J Med Phys 2022;47:10-9.
Accuracy of a dose calculation engine.\textsuperscript{[1]} Accuracy of dose estimation and reporting is an inherent feature of a dose computation engine. The American Association of Physicists in Medicine Task Group-329 has detailed about how various commercially available treatment planning systems (TPSs) deal with radiation transport and their dose deposition patterns in the clinic.\textsuperscript{[2]} Dose reporting (dose-to-water \( [D_w] \) and dose-to-medium \( [D_m] \)) is also a concern of utmost importance in contemporary clinic, as the International Atomic Energy Agency advocated the accuracy related to such systematic dosimetric issues should be organized within 1\%–2\%.\textsuperscript{[3]} Tissues have different chemical composition than water, resulting in different electron and photon interaction cross-sections. This in turn leads to difference in dose reported by different dose engines. Bragg–Gray cavity principle has been utilized to derive \( D_w \) from the \( D_m \) using unrestricted water to medium mass collision stopping power averaged over the energy spectra of primary electrons at a particular point.\textsuperscript{[4]} Apart from this, radiation beam size used for the treatment, incident photon energy, and density of medium has a direct impact on the radiation dose estimations. The precision of a dose calculation engine may have a huge impact on the radiation treatment outcome. With the advancements in the simulation and computation techniques, dose computation engines too have evolved with time. The dose calculation engine has been categorized into the following three categories: correction-based (type “a”), model-based (type “b”), and grid-based linear Boltzmann transport equation (LBTE) solver (type “c”).

The Acuros XB (AXB) algorithm is a grid-based LBTE solver that models the particle fluence for the interaction events occurring between radiation and matter. The AXB provides the deterministic solutions to the LBTE using iterative approach and applies medium appropriate-stopping power for obtaining the dose.\textsuperscript{[5]} The AXB solutions are akin to the gold standard, “Monte Carlo” solution for dose calculations in RT. The potential influence of AXB on various clinical sites has been reported in the literature, namely lung cancer,\textsuperscript{[6,7]} nasopharyngeal carcinoma,\textsuperscript{[8–11]} breast sarcoma,\textsuperscript{[12–14]} and prostate cancer.\textsuperscript{[15,16]} Rana et al.\textsuperscript{[13]} and Koo et al.\textsuperscript{[16]} reported that AXB deals more accurately with heterogeneity present for prostate cancer in comparison to analytical anisotropic algorithm (AAA) using RA technique.

Cervix carcinoma is a leading cause of morbidity among women, and RT forms an integral part of the treatment strategies in its management, especially in locally advanced cases. The radiation beams used for treatment of carcinoma cervix have to encounter a heterogeneous medium comprising air, bone, muscle, and soft tissues owing to its anatomical location. In this context, the present study aims to perform a comprehensive analysis of AXB and AAA computed dose distribution in patients suffering from carcinoma cervix using IMRT and RA technique and also investigate the potential impact of AXB computation on cervix carcinoma (for both dose-reporting modes, namely \( D_m \) and \( D_w \)). The analysis was executed based on the systematic as well as inter-patient variability between AXB and AAA algorithms. The present study tried to investigate whether switching from AAA to AXB has any bearing on prescription and dose–volume reporting for planning target volume (PTV) and OARs in carcinoma cervix radiotherapy.

**Materials and Methods**

**Patient selection, target delineation, and dose prescription**

A cohort of thirty patients suffering with cervix carcinoma (stages II–IIIb) and treated using RA and IMRT techniques were selected retrospectively. The appropriate accessories were used for patient immobilization and reproducibility of the treatment setup. The computed tomography (CT) scans were executed with a Siemens SOMATOM Sensation Open CT Scanner (Siemens Medical Systems, Germany) with full bladder as per departmental protocol using slice thickness of 3.0 mm. The target volume delineation was performed on the CT images as per the Radiation Therapy Oncology Group (RTOG) guidelines.\textsuperscript{[17]} The clinical target volume (CTV) included the cervix, uterus, and pelvic nodes including presacral and parametrical tissues. A margin of 5.0 mm was used isotropically to CTV to create PTV. The following OARs were also delineated: bowel, bladder, rectum, and femoral heads as per the standard RTOG definitions. The radiation treatment plans were optimized to deliver a prescription dose (PD) of 50.4 Gray (Gy) to the PTV in 28 fractions. The planning goal was to distribute 100\% PD to the 95\% of PTV with no more than 5\% of PTV volume receiving 110\% of PD. The dose to bladder and rectum was optimized in such a manner that \( V_{50\%} \) (volume receiving 50 Gy) should be less than 50\% of OAR volume.

**Planning and dose computation**

Treatment plans were generated using a 6 MV photon beam with a Millennium 120 multileaf collimator (MLC) using RA and IMRT techniques in Eclipse TPS version 11 (Varian Medical Systems, Palo Alto, USA). The IMRT plans were optimized for gantry angles: 60°, 100°, 135°, 180°, 225°, and 260°, and 300° without any collimator rotation, and RA plans were optimized using clockwise (CW, 179–181) and counterclockwise (CCW, 181–179) with collimator rotation of 10°–30°. The normal tissue objective was used in optimization process to spare the normal tissue. The Eclipse uses a separate optimizer, direct volume optimizer (DVO) for IMRT and progressive resolution optimizer for RA to play with the fluence map to achieve a clinically acceptable plan in adherence to the prescribed constraints. For IMRT, DVO optimizes the contour and intensity of radiation field using the simple gradient optimization approach to obtain the required dose–volume objectives. Further, the fluences were back-projected from the derivatives of the costs at each cloud point characterizing the patient volume. For RA, RPO optimizer is hinged on the postulation that complex issues like optimization of continuous variables, for example, MLC contour, MLC positions, and segment weights, pivot on the control point segmentation.
of the intact arc angle and could be illuminated in steps of continuously expanding the resolution without negotiating outcome accuracy. All treatment plans were computed using AAA and AXB version 11 under identical gantry and MLC setup. A grid resolution of 0.25 cm × 0.25 cm × 0.25 cm was utilized for dose computation for all treatment plans.

**Evaluation parameters**

Treatment plans were estimated using the dose–volume histogram (DVH), PTV was evaluated regarding mean dose, $D_{95\%}$ (dose to the 95% volume), $D_{98\%}$, $D_{99\%}$, and $V_{110\%}$ (volume receiving 110% of the PD), and maximum and minimum doses. The dose distribution was estimated utilizing the homogeneity index (HI), expressed as $(D_{2\%} - D_{98\%})/D_{98\%}$, and conformity index (CI), expressed as $(95\%$ isodose volume/PTV volume). The dose falloff around the PTV was assessed using gradient measure (GM), defined as the ratio of 50% and 100% prescription isodose volumes. The integral dose to the healthy tissue, i.e., normal tissue integral dose (NTID) is defined as area under the plot of differential absolute-dose, absolute-volume. NTID is estimated as product of mean dose and volume of healthy tissue outside the PTV, considering tissue having uniform density. The mean, maximum dose, and $D_{2\%}$ were estimated for OARs including $V_{50\text{ Gy}}$ for bladder and rectum using DVH data.

**Statistical analysis**

A detailed analysis was performed to examine the statistical difference between dose distributions calculated using AAA and AXB ($D_a$ and $D_b$) and their consistency across all the patients. The analysis was executed using a two-sample paired $t$-test (IBM SPSS version 20 [Armonk, NY: IBM Corp]) and Pitman–Morgan dispersion test (R Software version 3.4.2 [R Foundation for Statistical Computing, Austria]). $P < 0.05$ was regarded as statistically significant with confidence limit of 95%.

Pitman–Morgan test evaluates whether the ratio of variances of all dose–volume parameters was equivalent to one, looking at the comparison of AAA and AXB-D$_a$, AAA and AXB-D$_a$, and AXB-D$_a$ and AXB-D$_b$. As indicated in strategy proposed by Muñoz-Montplet et al.,[11] two situations can be distinguished when changing from AAA to AXB ($D_a$ or $D_b$) to support choice making:

(a) Inter-patient variability in dose–volume parameters is nonsignificant: The differences in the variances of respective dose–volume parameters were not statistically significant as a result of which a basic transformation factor can be used to determine dose prescriptions while switching between AXB and AAA computations

(b) Inter-patient variability in dose–volume parameters is significant: AXB cannot be a just scaled interpretation of AAA for this situation. No straightforward suggestions can be proposed.

**Results**

The present study analyzed the 180 treatment plans of 30 patients suffering from cervix carcinoma. Table 2a and b summarizes the dosimetric parameters for IMRT, Table 2a and b summarizes the dosimetric parameters for RA plans computed utilizing AAA and AXB ($D_a$ and $D_b$), respectively. Tables 3a and b encapsulate the categorization of dose–volume parameters while switching from AAA to AXB-D$_a$ computation as per the significance of the two statistical tests.

**Analytical anisotropic algorithm versus Acuros XB dose-to-medium**

For similar PTV coverage, there were slight decrease in mean, maximum, $D_{50\%}$, $D_{2\%}$, and $V_{110\%}$ and increase in $D_{98\%}$ and minimum dose for AAA-calculated IMRT and RA plans in comparison to AXB-D$_a$. The inter-patient variability was also nonsignificant except PTV $D_{50\%}$ (IMRT and RA), $D_{98\%}$ (RA), $D_{50\%}$ (IMRT), and $V_{110\%}$ (IMRT and RA).

For OARs, an increase in mean dose was observed for AAA-calculated IMRT and RA plans, except mean rectum dose in IMRT. The observed differences between two algorithms were larger for $V_{50\text{ Gy}}$ bladder (IMRT: 1.37% and RA: 1.01%), $V_{50\text{ Gy}}$ rectum (IMRT: 6.57% and RA: 3.81%), and $D_{2\%}$ for both femoral heads (right femur [IMRT: 1.04% and RA: 1.61%] and left femur [IMRT: 1.13% and RA: 1.43%]). In addition, inter-patient variability was also nonsignificant for most of the OARs, except mean rectum dose using IMRT technique, maximum dose to the bowel, and $D_{2\%}$ for bowel and left femoral head using RA technique, respectively.

The difference between both the algorithms was mainly with respect to NTID (IMRT: 0.06% and RA: 0.43%), MUs (IMRT: 1.14% and RA: 1.00%), CI (IMRT: 0.50% and RA: 1.00%), HI (IMRT: 6.33% and RA: 7.91%), and GM (IMRT: 0.15% and RA: 0.93%), respectively.

**Analytical anisotropic algorithm versus Acuros XB dose-to-water**

For similar PTV coverage, the two algorithms differed with respect to $D_{2\%}$ (IMRT: 0.85% and RA: 0.83%) and maximum dose inside PTV (IMRT: 1.64% and RA: 2.76%). The variability among patients was also nonsignificant excluding $D_{50\%}$ (IMRT), $D_{95\%}$, and $D_{2\%}$ for RA and $V_{110\%}$ (IMRT and RA), respectively.

For OARs, observed differences between two algorithms were for $V_{50\text{ Gy}}$ bladder (IMRT: 2.83% and RA: 3.70%), $V_{50\text{ Gy}}$ rectum (IMRT: 3.84% and RA: 0.93%), and $D_{2\%}$ for both femoral heads (right femur [IMRT: 2.06% and RA: 1.79%] and left femur [IMRT: 2.63% and RA: 2.52%]), respectively. The variability among patients was also nonsignificant excluding mean dose to bladder and both femoral heads and $D_{2\%}$ to bowel for IMRT and maximum dose to bladder, bowel, and both femoral heads for RA, respectively.

The differences observed between the two algorithms were with reference to NTID (IMRT: 0.51% and RA: 1.10%), MUs (IMRT: 0.28% and RA: 0.23%), CI (IMRT: 1.43% and RA: 2.23%), HI (IMRT: 7.03% and RA: 9.31%), and GM (IMRT: 2.51% and RA: 3.22%), respectively.
Table 1a: Dose-volume parameters for planning target volume using intensity-modulated radiation therapy technique for anisotropic analytical algorithm, Acuros XB dose-to-medium, and Acuros XB dose-to-water computations along with their systematic and inter-patient variability analysis

| Structure  | Parameters | AAA          | AXB-Dₘ        | AXB-Dₙ        | P         |
|------------|------------|--------------|---------------|---------------|-----------|
|             |            | AAA versus Dₘ | AAA versus Dₙ | Dₘ versus Dₙ  |           |
| PTV        | Mean       | 52.53±0.36   | 52.73±0.37    | 52.63±0.34    | 0.000     |
|            | D₅₀        | 50.40±0.01   | 50.40±0.01    | 50.40±0.01    | 0.575     |
|            | D₅₅        | 49.48±0.25   | 49.42±0.28    | 49.46±0.25    | 0.010     |
|            | D₇₀        | 52.55±0.62   | 52.80±0.42    | 52.63±0.38    | 0.023     |
|            | D₉₀        | 55.08±0.73   | 55.49±0.71    | 55.56±0.67    | 0.000     |
|            | V₁₁₀       | 1.82±2.21    | 3.03±3.63     | 2.96±2.68     | 0.001     |
| Maximum    | 58.70±1.46  | 59.04±1.24   | 59.69±1.60    | 0.029     |
| Minimum    | 42.13±2.53  | 41.31±2.54   | 41.83±2.66    | 0.010     |
| NTID       |            | 311.10±56.44 | 311.51±57.60 | 309.79±57.58 | 0.525     |
| MUs        |            | 1644.66±300.29 | 1663.20±299.63 | 1649.70±304.32 | 0.000     |
| CI         |            | 1.02±0.02    | 1.03±0.02     | 1.04±0.03    | 0.029     |
| HI         | 0.107±0.016 | 0.115±0.016  | 0.115±0.016   | 0.000     |
| GM         | 4.280±0.501 | 4.276±0.517  | 4.177±0.498   | 0.568     |

AAA: Anisotropic analytical algorithm, AXB-D: Acuros XB, Dₘ: Dose-to-medium, Dₙ: Dose-to-water, PTV: Planning target volume, CI: Conformity index, HI: Homogeneity index, GM: Gradient measure, NTID: Normal tissue integral dose, MUs: Monitor units

Table 1b: Dose-volume parameters for organs at risk using intensity-modulated radiation therapy technique for anisotropic analytical algorithm, Acuros XB dose-to-medium, and Acuros XB dose-to-water computations along with their systematic and inter-patient variability analysis

| Parameters | AAA          | AXB-Dₘ        | AXB-Dₙ        | P         |
|------------|--------------|---------------|---------------|-----------|
|            | AAA versus Dₘ | AAA versus Dₙ | Dₘ versus Dₙ  |           |
| Bladder    | Mean         | 40.53±1.98    | 40.49±1.97    | 40.61±2.05 | 0.034     |
|            | V₅₀         | 34.85±5.54    | 35.37±5.87    | 35.82±5.40 | 0.016     |
|            | Maximum     | 57.03±1.39    | 57.14±1.27    | 57.32±1.30 | 0.216     |
|            | D₅₀         | 54.30±0.71    | 54.45±0.74    | 54.65±0.73 | 0.000     |
| Rectum     | Mean         | 42.23±3.74    | 42.34±3.80    | 42.28±3.79 | 0.001     |
|            | V₅₀         | 26.31±9.62    | 26.12±9.90    | 27.28±9.30 | 0.000     |
|            | Maximum     | 55.27±1.19    | 55.55±1.15    | 55.56±1.11 | 0.001     |
|            | D₅₀         | 53.31±0.79    | 53.62±0.84    | 53.61±0.82 | 0.000     |
| Bowel      | Mean         | 18.61±3.43    | 18.04±3.43    | 17.85±3.44 | 0.000     |
|            | Maximum     | 51.36±3.69    | 51.86±3.88    | 51.35±3.70 | 0.000     |
|            | D₅₀         | 40.87±4.86    | 40.11±4.84    | 40.45±4.94 | 0.046     |
| Left femoral head | Mean     | 25.59±5.84    | 25.37±5.79    | 26.12±6.05 | 0.001     |
|            | Maximum     | 52.80±3.13    | 52.44±3.22    | 53.77±3.21 | 0.002     |
|            | D₅₀         | 46.18±5.31    | 45.70±5.49    | 47.44±5.58 | 0.004     |
| Right femoral head | Mean   | 25.62±5.20    | 25.41±5.14    | 26.15±5.32 | 0.002     |
|            | Maximum     | 53.05±2.61    | 53.19±2.86    | 54.47±2.67 | 0.403     |
|            | D₅₀         | 47.97±4.10    | 47.12±4.19    | 48.60±4.18 | 0.012     |

AXB-D: Acuros XB, Dₘ: Dose-to-medium, Dₙ: Dose-to-water, AAA: Anisotropic analytical algorithm

Acuros XB dose-to-medium versus Acuros XB dose-to-water

For similar PTV coverage, the observed differences between the algorithms were in maximum (IMRT: 1.10% and RA: 1.11%) and minimum dose inside PTV (IMRT: 1.31% and RA: 1.39%). The inter-patient variability was nonsignificant of most of the parameters except V₁₁₀ using both treatment techniques.

For OARs, observed larger differences between two algorithms were for V₅₀ bladder (IMRT: 1.59% and RA: 3.01%), V₅₀ rectum (IMRT: 2.42% and RA: 2.37%), and D₅₀ for both femoral heads (right femur [IMRT: 3.19% and RA: 3.50%] and left femur [IMRT: 3.88% and RA: 4.05%]), respectively. The inter-patient variability was nonsignificant of most of the OARs except mean dose to bladder and left femoral head using IMRT technique, mean dose to both the femoral heads, and maximum dose to the bladder using RA technique, respectively.

The differences between both the algorithms were NTID (IMRT: 0.56% and RA: 0.66%), MUs (IMRT: 0.86% and RA: 0.77%),
CI (IMRT: 0.93% and RA: 1.27%), HI (IMRT: 0.85% and RA: 1.68%), and GM (IMRT: 2.29% and RA: 2.22%), respectively.

Figures 1 and 2 show the variations in mean value and the density plots (similarity of variance using Pitman–Morgan test) for (a) PTV $D_{20\%}$, (b) left femur $D_{2\%}$, and (c) right femur $D_{2\%}$ for IMRT and RA plans computed using AAA, AXB-D$_m$, and AXB-D$_w$ for individual patients, respectively. The density plot is the smoothed version of histogram (independent of the number of bins used) and illustrates the distribution of a numeric variable employing the kernel density estimates to depict the probability density function. Figure 3 illustrates the outline of mean difference and CI % for the various parameters of PTV and OARs between (a) AAA-AXB-D$_m$, (b) AAA-AXB-D$_w$, and (c) AXB-D$_m$-AXB-D$_w$ using IMRT and RA.

**Discussions**

The present study details no significant difference in target coverage for IMRT and RA treatment plans computed
Table 3a: Arrangement of the dose-volume parameters while switching from anisotropic analytical algorithm to Acuros XB dose-to-medium computation as per the significance of the statistical test

| D_{w} | IMRT | RA |
|-------|------|-----|
|       | Nonsignificant | Significant | Nonsignificant | Significant |
| Dose-volume parameters inter-patient variability | NTID, GM | PTV: Mean, D_{50Gy}, D_{2\%} | PTV: Mean, D_{50Gy}, D_{2\%}, Maximum, minimum, MUs, CI, HI | Bladder: D_{2\%} | Rectum: Mean |
|       | Significant | PTV: Maximum, minimum, MUs, CI, HI | Bladder: Mean, V_{50Gy}, D_{2\%} | Rectum: V_{50Gy}, maximum, D_{2\%} | Bowel: Mean, maximum, D_{2\%} | PTV: D_{50Gy}, V_{110Gy}, Rectum: Mean |
|       | PTV: D_{50Gy}, V_{110Gy}, Rectum: Mean | Bladder: Mean, V_{50Gy}, D_{2\%} | Rectum: Mean | PTV: D_{50Gy,7} D_{58\%} | MU | Bowel: Maximum, D_{2\%} | Left femur: D_{2\%} |

IMRT: Intensity-modulated radiation therapy, RA: RapidArc, GM: Gradient measure, PTV: Planning target volume, CI: Conformity index, HI: Homogeneity index, D_{w}: Dose-to-water, NTID: Normal tissue integral dose, MUs: Monitor units

Table 3b: Arrangement of the dose-volume parameters while switching from anisotropic analytical algorithm to Acuros XB dose-to-water computation as per the significance of the statistical test

| D_{w} | IMRT | RA |
|-------|------|-----|
|       | Nonsignificant | Significant | Nonsignificant | Significant |
| Dose-volume parameters inter-patient variability | PTV: D_{50Gy}, D_{95\%}, D_{2\%}, minimum | PTV: Mean, maximum, NTID, MU, CI, HI, GM | Bladder: D_{2\%} | Rectum: Mean |
|       | Significant | Bladder: Mean, V_{50Gy}, D_{2\%} | Bowel: Mean, Maximum left femur: Maximum, D_{2\%} | Right femur: Maximum, D_{2\%} | PTV: D_{50Gy} D_{2\%} | Bladder: Maximum |
|       | PTV: D_{50Gy} D_{2\%} | Bladder: Mean | Right femur: Mean |

IMRT: Intensity-modulated radiation therapy, RA: RapidArc, GM: Gradient measure, PTV: Planning target volume, CI: Conformity index, HI: Homogeneity index, D_{w}: Dose-to-water, NTID: Normal tissue integral dose, MUs: Monitor units

using AAA, AXB-Dm and AXB-Dw algorithm. This can be attributed to the fact that treatment plans were normalized to 95% isodose line for dosimetric evaluation compared to other dosimetric parameters (i.e., D_{98\%}, D_{max}, D_{min} etc.). The main findings of the study were as follows: (1) all dose–volume parameters were higher for AXB-D_{w} in comparison to AAA for IMRT and RA plans, except D_{50Gy}, minimum dose to PTV, and rectum mean dose (RA). (2) There was no systematic trend found in dose–volume parameters for the target and OARs between AXB-D_{m} and AXB-D_{w} for IMRT and RA plans. (3) The dose–volume parameters for target were higher for AXB-D_{m} in comparison to AAA in IMRT and RA plans, except PTV D_{50Gy} and minimum dose to PTV. Bladder and rectum were also pursuing the drift except bladder mean dose, bladder D_{2\%} (RA), and mean dose to rectum (RA). On the contrary, dose–volume parameters for femoral heads were higher for AAA in comparison to AXB-D_{m} in IMRT and RA plans, except maximum dose to the left femoral head in IMRT.

In all cases, the largest systematic difference was found in V_{50Gy}, of rectum and D_{2\%} of femoral heads using IMRT and RA techniques, respectively. AAA predicts significantly lower CI, HI, and MUs in contrast to AXB-D_{m} and AXB-D_{w} for IMRT and RA plans. On the contrary, AAA predicts higher NTID and GM in contrast to AXB-D_{m} and AXB-D_{w} for IMRT and RA plans.

The present study reveals that AAA predicts lower maximum and higher minimum doses to PTV compared to AXB-D_{m} and AXB-D_{w}. Rana et al.\textsuperscript{[15]} studied the dosimetric impact of AXB-D_{m} on prostate cancer using RA and concluded no significant contrast between AAA and AXB-D_{m}. In that study, AAA estimates higher minimum and maximum doses to the target. In another study, Koo et al.\textsuperscript{[16]} reported lower maximum and higher minimum doses to target for AAA in comparison to those calculated using AXB-D_{m} for prostate RA technique using endorectal balloon. Kumar et al.\textsuperscript{[21]} also detailed the use of AXB on cervix carcinoma using RA technique compared to AAA.
The average difference between AAA, AXB-\(D_m\), and AXB-\(D_w\) was \(<1.0\%\) for mean dose to PTV and OARs, except mean dose to the femoral heads with a maximum difference of \(4.05\%\) (RA, AXB-\(D_m\) versus AXB-\(D_w\)). This higher difference...
in the femoral doses occurs due to its composition (Stopping power ratio of cartilage and cortical bone is 1.035 and 1.111, respectively).[22] Zifodya et al.[23] reported an average difference of 2% for mean dose to PTV and OARs among AAA, AXB-D$_m$, respectively.
and AXB-Dw and a maximum difference of 4.6% between AXB-Dm and AXB-Dw in nonwater biological medium (i.e., compact bone). Fogliata et al. [24] also reported a comparable finding with AXB-Dm estimating 5% higher doses in the bone contrast to AXB-Dw. These differences in AXB-Dm and AXB-Dw computations occur due to the difference in stopping power ratio of water and material of different densities.

The present study reveals that higher systematic significant difference exists in volume of rectum receiving 50 Gy among AAA, AXB-Dm and AXB-Dw. This can be attributed due to the presence of air/gas heterogeneity in rectum. In a measurement study with low-density heterogeneous medium, Kumar et al. [23] reported that AXB predicts fewer discrepancies (1.3%–2.2%) with ion chamber measurements than the AAA (1.6% to −3.6%) in low-density medium. Koo et al. [16] reported better agreement in air cavity and air tissue interface for AXB calculation compared to those AAA calculated. Further, Koo et al. [16] reported that for precise rectal dose analysis in prostate cancer, AXB should be considered over AAA.

Pitman–Morgan test was performed on the dose distribution calculated via AAA, AXB-Dm and AXB-Dw to evaluate the significant difference in variances of the computed dose distributions. Analysis estimated less inter-patient variability while switching from AAA to AXB-Dm in comparison to those switching from AAA to AXB-Dw. The results acquired in the present study could assist in decision-making in clinic when adopting AXB algorithm for carcinoma cervix using IMRT and RA techniques. For example, V50 cm3 rectum was higher (6.57% – IMRT and 3.81% –RA) for AXB-Dm, and in addition, inter-patient variability was nonsignificant. It was corresponded to situation (a); therefore, the increased probability of rectal toxicity may not be expected for higher values of AXB-Dm. In addition, the same situation was noticed for PTV D98, while switching from AAA to AXB-Dm and from AAA to AXB-Dw using RA technique, respectively. Despite these outcomes, it is essential to accentuate that inter-patient variability was too high to even consider establishing the basic suggestions for most of the parameters, and it is corresponding to the situation (b) in both cases, i.e., while switching from AAA to AXB-Dm or AAA to AXB-Dw. In these cases, further clinical investigations are required in regard to forecast of clinical results from the dose–volume parameters determined by AXB at the point, when they contrast from the dose–volume parameters determined with AAA, which supports the contemporary clinical knowledge. A similar result has been reported by Muñoz-Montplet et al. [11] for head-and-neck cancer, while evaluating the impact of AXB (Dm and Dw dose-reporting modes) on volumetric-modulated arc therapy technique. Nevertheless, it was not possible to establish a simple recommendation based on the inter-patient variability in the results due to its dosimetric nature of the study and cohort size. In these situations, further studies are still required to draw the conclusion for clinical outcomes from dose–volume parameters calculated using AXB algorithm in comparison to AAA algorithm calculated dose–volume parameters.

**Conclusions**

The present study reveals the important difference between AAA, AXB-Dm, and AXB-Dw computations for cervix carcinoma using IMRT and RA techniques. The inter-patient variability and systematic difference in dose–volume parameters computed using AAA, AXB-Dm, and AXB-Dw algorithms present the possible impact on the dose prescription to PTV and their relative constraints to OARs for IMRT and RA techniques. This may help in decision-making in clinic while switching from AAA to AXB (Dm or Dw) algorithm for cervix carcinoma using IMRT and RA techniques.

**Acknowledgments**

We also extend our special thanks to Dr. Carles Muñoz-Montplet, Medical Physics and Radiation Protection Department, Institut Català d’Oncologia, Avda. França s/n, 17007 Girona, Spain for his kind support and suggestions in data analysis and forest plots in R program.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Kry SF, Feygelman V, Balter P, Knöös T, Charlie Ma CM, Snyder M, et al. AAPM Task Group 329: Reference dose specification for dose calculations: Dose-to-water or dose-to-muscle? Med Phys 2020;47:e52-64.
2. Internal Atomic Energy Agency. Accuracy Requirements and Uncertainties in Radiotherapy. IAEA Human Health Series Report No. 31. Vienna: Internal Atomic Energy Agency; 2016.
3. Kry SF, Lye J, Clark CH, Andratschke N, Dimitriadis A, Followill D, et al. Report dose-to-medium in clinical trials where available; a consensus from the Global Harmonisation Group to maximize consistency. Radiother Oncol 2021;159:106-11.
4. Cabanas ML, Yan C, Lalonde RJ, Heron DE, Huq MS. Which dose specification should be used for NRG radiation therapy trials: Dose-to-medium or dose-to-water? Pract Radiat Oncol 2020;10:e103-10.
5. Wareing TA, McGhee JM, Morel JE, Fautz SD. Discontinuous finite element Sm methods on three-dimensional unstructured grids. Nucl Sci Eng 2001;138:256-68.
6. Fogliata A, Nicolini G, Clivio A, Vanetti E, Cozzi L. Critical appraisal of Acuros XB and Anisotropic Analytic Algorithm dose calculation in advanced non-small-cell lung cancer treatments. Int J Radiat Oncol Biol Phys 2012;83:1587-95.
7. Rana S, Rogers K, Pohkarel S, Cheng C. Evaluation of Acuros XB algorithm based on RTOG 0813 dosimetric criteria for SBRT lung treatment with RapidArc. J Appl Clin Med Phys 2014;15:4474.
8. Kan MW, Leung LH, Yu PK. Dosimetric impact of using the Acuros XB algorithm for intensity modulated radiation therapy and RapidArc planning in nasopharyngeal carcinomas. Int J Radiat Oncol Biol Phys 2013;85:e73-80.
9. Kroon PS, Hol S, Essers M. Dosimetric accuracy and clinical quality of Acuros XB and AAA dose calculation algorithm for stereotactic and conventional lung volumetric modulated arc therapy plans. Radiat Oncol 2013;8:149.
10. Kamaleldin M, Elsherbini NA, Elshemy WM. AAA and AXB algorithms for the treatment of nasopharyngeal carcinoma using IMRT and RapidArc techniques. Med Dosim 2018;43:224-9.
11. Muñoz-Montplet C, Marruecos J, Buxó M, Jurado-Bruguéman D, Romero-Martínez I, Bueno M, et al. Dosimetric impact of Acuros XB dose-to-water and dose-to-medium reporting modes on VMAT planning.
for head and neck cancer. Phys Med 2018;55:107-15.
12. Fogliata A, Nicolini G, Clivio A, Vanetti E, Cozzi L. On the dosimetric impact of inhomogeneity management in the Acuros XB algorithm for breast treatment. Radiat Oncol 2011;6:103.
13. Guebert A, Conroy L, Weppler S, Alghamdi M, Conway J, Harper L, et al. Clinical implementation of AXB from AAA for breast: Plan quality and subvolume analysis. J Appl Clin Med Phys 2018;19:243-50.
14. Kumar L, Kishore V, Bhushan M, Dewan A, Yadav G, Raman K, et al. Impact of acuros XB algorithm in deep-inspiration breath-hold (DIBH) respiratory techniques used for the treatment of left breast cancer. Rep Pract Oncol Radiother 2020;25:507-14.
15. Rana S, Rogers K, Lee T, Reed D, Biggs C. Dosimetric impact of Acuros XB dose calculation algorithm in prostate cancer treatment using RapidArc. J Cancer Res Ther 2013;9:430-5.
16. Koo T, Chung JB, Eom KY, Seok JY, Kim IA, Kim JS. Dosimetric effects of the acuros XB and anisotropic analytical algorithm on volumetric modulated arc therapy planning for prostate cancer using an endorectal balloon. Radiat Oncol 2015;10:48.
17. Radiation Therapy Oncology Group (RTOG-0418) Protocol: A Phase II Study of Intensity Modulated Radiation Therapy (IMRT) to the Pelvis +/- Chemotherapy for Post. Operative Patients with either Endometrial or Cervical Carcinoma. Available from: http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=0418. [Last assessed on 2021 Jan 20].
18. Kumar L, Yadav G, Kishore V, Bhushan M, Gairola M, Tripathi D. Validation of the RapidArc delivery system using a volumetric phantom as per Task Group Report 119 of the American Association of Physicists in Medicine. J Med Phys 2019;44:126-34.
19. Kumar L, Yadav G, Samuvel KR, Bhushan M, Kumar P, Suhail M, et al. Dosimetric influence of filtered and flattening filter free photon beam on rapid arc (RA) radiotherapy planning in case of cervix carcinoma. Rep Pract Oncol Radiother 2017;22:10-8.
20. Kumar L, Yadav G, Raman K, Bhushan M, Pal M. The dosimetric impact of different photon beam energy on RapidArc radiotherapy planning for cervix carcinoma. J Med Phys 2015;40:207-13.
21. Kumar L, Kishore V, Bhushan M, Kumar P, Chaudhary RL. Dosimetric impact of Acuros XB on cervix radiotherapy using RapidArc technique: A dosimetric study. Rep Pract Oncol Radiother 2021;26:582-9.
22. Bharati A, Mandal S, Srivastava A, Rastogi M, Khurana R, Hadi R, et al. Evaluation of clinical implications in the use of dose to water versus dose to medium using NTCP and TCP models for urinary bladder tumors. Pol J Med Phys Eng Pol J Med Phys Eng 2021;27:19-24.
23. Zifodya JM, Challens CH, Hsieh WL. From AAA to Acuros XB-clinical implications of selecting either Acuros XB dose-to-water or dose-to-medium. Australas Phys Eng Sci Med 2016;39:431-9.
24. Fogliata A, Scorsetti M, Navarria P, Catalano M, Clivio A, Cozzi L, et al. Dosimetric comparison between VMAT with different dose calculation algorithms and protons for soft-tissue sarcoma radiotherapy. Acta Oncol 2013;52:545-52.
25. Kumar L, Yadav G, Kishore V, Bhushan M. Dosimetric validation of Acuros XB photon dose calculation algorithm on an indigenously fabricated low density heterogeneous phantom. Radiat Prot Environ 2019;42:173-9.